MangoRx Review

What MangoRx charges

• Sermorelin: $185/mo — the treatment block prints "Starting at" above "$185 Monthly"
• NAD+: $200/mo — the treatment block prints "Starting at" above "$200 Monthly"

The figure is on the page, but only after it renders

Each of the two compounds sold here has its own page, and each page carries a treatment block with the compound name, its chemical name and a starting figure with the billing period written beside it.

That block is the whole of what this seller publishes about price, and it is enough: a reader learns the compound, the starting rate and the period without opening an intake.

What a reader fetching the page rather than viewing it would find is nothing. The figure is absent from the served markup and arrives only in the hydration payload the browser unpacks.

This site treats a figure in a hydration payload as unpublished, so both rows here were read from the rendered block rather than from the page source.

A pharmacy described down to its accreditations, and never named

The FAQ answers its own compounding question with a state, two accreditation bodies and a certification programme. It is a specific answer.

It is also an answer with no name in it. A reader cannot look the facility up, cannot check its inspection history, and cannot tell whether it is the same one filling a different product.

This site records the pharmacy flag on a name and nothing else, precisely because a description this detailed reads like a disclosure while withholding the one fact that would make it checkable.

The seller does say a customer may use a pharmacy of their own choosing, while noting results cannot be guaranteed outside its partner network.

The state answer is the seller's own question

The FAQ page carries, in its own words, a question asking why MangoRx is available only in certain states, which settles the coverage flag without any inference on our part.

The answer names three reasons — telehealth law, whether a treatment may be delivered by telehealth at all, and licensing eligibility — and invites a reader in an unserved state to join a notification list.

Several other questions on the same page ask which states a specific product is not approved in, which suggests coverage differs by product as well as by state.

No list is published for any of them, so this row stores no states and a reader settles eligibility inside the intake.

Bloodwork belongs to a different product line

Nineteen questions on the FAQ page concern bloodwork: what is acceptable, where to get it, what format, what the cutoff is, and whether it is included.

Every one of them is scoped to the testosterone protocol. Neither peptide page mentions lab work at all, in either direction.

It would be easy to read that volume of bloodwork discussion as a lab-inclusive service and set the flag accordingly. It would also be reading a different product's fact onto these two.

So the lab flag is false here on absence rather than on denial, which is a weaker finding and is recorded as one.

How we verified this

• Rendered both product pages in a browser and read the figures out of the laid-out treatment block, not out of the page source.
• Confirmed the served markup carries the figures only inside a hydration payload, and treated that as unpublished.
• Fired two nonsense paths at this host in the same pass and rendered both; one answered with a success status and still laid out a not-found document, so no claim here rests on a status code.
• Opened every collapsed question on the FAQ page one at a time and read the answers, rather than reading the questions and inferring the answers.
• Read the compounding answer for a name, found a state and two accreditations instead, and set the pharmacy flag false on that.
• Took the coverage finding from the seller's own question about why it is available only in certain states, rather than from any absence of a list.
• Checked every bloodwork answer for its scope and found all of them attached to a different product line.
• Screened this seller in the live federal warning-letter record by brand, with a known-good positive control and a nonsense negative control fired in the same run, and read the company column rather than accepting a full-text match.